» Articles » PMID: 39458044

Amiodarone Therapy: Updated Practical Insights

Abstract

Amiodarone, a bi-iodinated benzofuran derivative, is among the most commonly used antiarrhythmic drugs due to its high level of effectiveness. Though initially categorized as a class III agent, amiodarone exhibits antiarrhythmic properties across all four classes of antiarrhythmic drugs. Amiodarone is highly effective in maintaining sinus rhythm in patients with paroxysmal atrial fibrillation while also playing a crucial role in preventing a range of ventricular arrhythmias. Amiodarone has a complex pharmacokinetic profile, characterized by a large volume of distribution and a long half-life, which can range from several weeks to months, resulting in prolonged effects even after discontinuation. Side effects may include thyroid dysfunction, pulmonary fibrosis, and hepatic injury, necessitating regular follow-ups. Additionally, amiodarone interacts with several drugs, including anticoagulants, which must be managed to prevent adverse effects. Therefore, a deep understanding of both oral and intravenous formulations, as well as proper dosage adjustments, is essential. The aim of this paper is to provide a comprehensive and updated review on amiodarone's indications, contraindications, recommended dosages, drug interactions, side effects, and monitoring protocols.

Citing Articles

Impact of Preventive Intravenous Amiodarone on Reperfusion Ventricular Fibrillation in Patients With Left Ventricular Hypertrophy Undergoing Open-Heart Surgery: Randomized Controlled Clinical Trial.

Gong C, Zhou X, Zhang Z, Fang Y JMIR Form Res. 2025; 9():e64586.

PMID: 39806934 PMC: 11745488. DOI: 10.2196/64586.

References
1.
Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M . Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001; 29(6):1149-53. DOI: 10.1097/00003246-200106000-00011. View

2.
Dasu N, Khalid Y, Panuganti S, Daly S . Amiodarone induced epididymo-orchitis. Urol Case Rep. 2019; 26:100929. PMC: 6556547. DOI: 10.1016/j.eucr.2019.100929. View

3.
Nayak B, Hodak S . Hyperthyroidism. Endocrinol Metab Clin North Am. 2007; 36(3):617-56, v. DOI: 10.1016/j.ecl.2007.06.002. View

4.
Ruzieh M, Moroi M, Aboujamous N, Ghahramani M, Naccarelli G, Mandrola J . Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo. Am J Cardiol. 2019; 124(12):1889-1893. DOI: 10.1016/j.amjcard.2019.09.008. View

5.
Passman R, Bennett C, Purpura J, Kapur R, Johnson L, Raisch D . Amiodarone-associated optic neuropathy: a critical review. Am J Med. 2012; 125(5):447-53. PMC: 3322295. DOI: 10.1016/j.amjmed.2011.09.020. View